Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.hVIVO, is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases, has signed two new contracts with global biopharmaceutical company for two respiratory syncytial virus (RSV) human challenge studies.
Image: hVIVO has signed new contracts with global biopharmaceutical firm. Photo: courtesy of rawpixel / Unsplash.
Subscribe to our email newsletter
The two studies are projected to deliver a total of c.£9m in revenue, with most of the revenue being recognised in 2019.
These contracts are in addition to the RSV human challenge study contract, with a large research and development-focused biotechnology company for the value of £11.9m, which the Company announced in September 2018 and is due to commence in our quarantine unit later this month. The revenue from this study is also expected to be fully recognised by the end of 2019.
hVIVO executive chairman Dr Trevor Phillips said: “We are pleased to have signed these two contracts with this global biopharmaceutical company. The recent significant new contract wins reinforce our leading position in human disease models based upon viral and allergen challenge and are a testament to our industry leading RSV-human challenge model.
“We have the strongest sales pipeline we have had for several years. We remain actively engaged in several discussions with other pharmaceutical companies for contracting studies across our current challenge portfolio, including allergen, asthma, human rhinovirus, influenza and RSV.
“We continue to experience high levels of interest from leading global pharmaceutical companies for the development of new challenge models in RSV, asthma and chronic obstructive pulmonary disease. With the significant demand for our services across the entire portfolio, we expect to convert a growing number of these opportunities into contracts that will further validate our service offerings and enhance our revenue in 2019 and beyond.”
hVIVO is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases.
Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.
Source: Company Press Release
